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Abstract  
Objective: Inhibitory receptors (IRs) are essential to regulate effector immune responses and 
may play critical roles during autoimmune diseases. In Rheumatoid Arthritis (RA), we 
evaluated whether IR expression on T cells showed correlation with immune activation, 
disease activity and response to treatment as well as if IR-mediated pathways were 
functional.  
 





 T cells from blood and synovial fluid of RA patients ex vivo and after 
culture. All the parameters were correlated with disease activity score (DAS28) and response 
to treatment.  
 
Results: In RA patients with low activation of T cells, IRs expression showed an inverse 
relationship with DAS28. Frequencies of T cells expressing multiple IRs were reduced in 
untreated RA patients but recovered normal levels in treated patients. RA patients that 
responded to treatment, showed augmented frequency of IRs-expressing T cells that 
correlated with reduced inflammatory cytokine production in comparison to non-responders. 
Synovial fluid was enriched in effector and memory T cells expressing multiple IRs. 
Remarkably, inhibitory pathways were operative in blood and synovial T cells from all RA 
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Conclusion: IR expression on T cells from RA patients inversely correlated with effector T 
cell function and disease activity and may predict response to treatment. Furthermore, 
different inhibitory pathways are functional and cooperatively suppress synovial T cells, 
providing a rationale for new treatment strategies to regulate acute local inflammation. 
 
Rheumatoid arthritis (RA) is a common chronic autoimmune disease (AID) characterized by 
persistent synovitis and systemic inflammation that frequently results in cartilage erosion and 
bone injury (1). Current consensus indicates that RA development is attributable to genetic 
and environmental factors, as well as abnormalities in innate and adaptive immunity (2). 
Within the multifactorial events and multiple immune mediators that participate in RA, T 
cells are linked to RA pathogenesis at different levels including initiation, progression and 
perpetuation (3, 4). Indeed, T cells expand and accumulate in the synovia, producing 
cytokines and mediators that sustain inflammation (5, 6). 
Considering that AIDs such as RA are characterized by persistent activation of T cells, 
pathways that regulate T cell expansion and function may modulate disease pathogenesis. 
Indeed, co-inhibitory pathways have been shown to affect self-tolerance and autoimmunity 
(7). Lately, inhibitory receptors (IRs) including PD-1 (Programmed cell death protein 1), 
CTLA4 (cytotoxic T-lymphocyte-associated protein 4), CD160, BTLA (B- and T- 
lymphocyte attenuator), Tim-3 (T-cell immunoglobulin and mucin-domain containing-3), 
TIGIT (T cell immunoreceptor with Ig and ITIM domains) and others have emerged as key 
players in the control of T cell effector responses in chronic infections and cancer (8). IR 
expression is induced during the initial stages of T cell activation and is also associated to a 
terminal differentiation state termed “T cell exhaustion” characterized by the presence of 
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defined and the few existing reports focused at individual inhibitory pathways. In particular, 
the PD-1/PD-L1 pathway has been involved in the regulation of local and peripheral T cell 
effector function (10-13). Recently, transcriptome studies in T cells from patients with 
different AIDs (including RA) linked gene expression patterns of T cell exhaustion to a 
favorable long-term clinical outcome characterized by fewer relapses (14). Altogether, these 
evidences suggest that studying the expression and role of IRs on T cells from RA patients 
may provide useful information regarding the status of the ongoing inflammation and disease 
progression. Furthermore, these data will be helpful to establish whether manipulating 
inhibitory pathways could be beneficial to control the long term course of the disease. 
In this study, we evaluated the expression of activation markers and multiple IRs in T cells 
from blood and synovial fluid of RA patients. Furthermore, we determined the correlation 
between these markers, the activity of the disease and the response to treatment. Finally, we 
established that the inhibitory pathways mediated by PD-1/PD-L1 and HVEM/CD160/BTLA 
are operative to regulate proliferation and cytokine production of T cells from RA patients. 
 
Material and Methods 
Patients. RA patients and healthy donors (HD) were recruited from the Rheumatology 
Service (Hospital Nacional de Clínicas, Córdoba, Argentina). RA patients were diagnosed 
according to the American College of Rheumatology and the European League Against 
Rheumatism (EULAR) classification criteria (15). Exclusion criteria included known or 
suspected ongoing infections or metabolic diseases for RA patients and any history of 
autoimmune disease or immunosupressive therapy for HD. RA disease activity score 
(DAS28-ESR) was assessed at the time of blood collection as described(16) and RA patients 
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RA patients were classified as untreated (treatment-naïve or without treatment in the last 6 
months), DMARDs-treated (mainly methotrexate) and anti-TNF+/-DMARDs (any TNF 
blocking biological treatment plus methotrexate mainly). Response to treatment was defined 
according to EULAR criteria (1, 17): responders patients (rRA) showed a reduction in 
ΔDAS28 >1,2 while non-responders patients (nrRA) exhibited ΔDAS28 ≤1,2  after 3 month 
of treatment. 
 
The study was approved by the Institutional Ethics Committee and performed according to 
the Declaration of Helsinki on studies with human subjects. All subjects provided written 
informed consent prior to any study procedure.  
 
Specimens and cell separation. Peripheral blood (PB) was drawn from RA patients and HD. 
Information describing the study subjects is shown in Table 1. Serum samples were obtained 
for immunological laboratory determinations (Details in Supplementary Materials and 
Methods). Synovial fluid (SF) was collected from patients with active disease whenever 
possible. Mononuclear cells (MCs) from PB and SF were isolated by centrifugation in Ficoll-
Hypaque density gradients (GE Healthcare Bio-Science AB) and cryopreserved for future 
determinations.  
 
Flow cytometry and cell sorting. Flow cytometry for detection of surface molecules, 
intracellular cytokines and intranuclear transcription factors was performed according 
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 T cells (0,1x10
6
) were resuspended in PBS-FBS 1%, stained with 
1μM Carboxyfluorescein succinimidyl ester (CFSE) and stimulated in 96-well plates (Costar, 
flat bottom) pre-coated overnight with anti-CD3 1 μg/ml (OKT3, Biolegend) and anti-CD28 
0,5 μg/ml (CD28.2, Biolegend) in presence or absence of soluble blocking anti-CD160 (CL1-
R2, MBL, 2μg/ml) or anti-PD-1 (J116, eBiosciences, 10μg/ml), plate-bound agonistic 
HVEM:Fc (Biolegend, 5μg/ml) and/or PDL1:Fc (R&D Systems, 5μg/ml). At the end of the 
stimulation (3 days for neutralization and 6 days for receptor ligation), cells were stimulated 
with PMA/Ionomycin to determine cytokine production. Proliferation was determined as 
CFSE dilution or detection of the proliferation marker Ki-67 (anti-Ki67 eFluor660, SolA15, 
eBioscience). Fixable Viability Stain 780 was used for exclusion of dead cells. 
Proliferation index was calculated as the ratio between the percentage cell proliferation in 
cells stimulated with anti-CD3/anti-CD28 plus anti-CD160, HVEM:Fc and/or PD-L1:Fc and 
the percentage of proliferation in cells stimulated only with the mitogen. 
Statistics. Statistical analyses were performed with GraphPad Prism 7 software. P values 
<0.05 were considered significant. The D´Agostino-Pearson omnibus normality test was 
initially performed to determine the distribution of the datasets. The specific tests used are 


















 T cells from RA patients showed different levels of IR expression according to 
their activation status 
High expression of IRs has been described at different stages of T cell life. On one side, 
several IRs are upregulated in recently activated T cells that exhibit strong effector function 
(18) and may boost RA progression. On the other side, IRs expression is a hallmark of 
terminally differentiated exhausted cells (19), whose poor effector activity may be desirable 
in the context of RA. Therefore, the evaluation of the activation status is an essential first step 
to understand the significance of IR expression on T cells during RA. As measure of 
activation, we determined the expression of CD69 on T cells from RA patients with active 




 T cells were present in similar frequencies in 
PB from RA patients and HD (data not shown), both T cell subsets showed an increased 
frequency of CD69
+
 cells in RA patients, indicating a status of high activation (Figure 1A). 
Of note, the highest frequencies of activated CD69
+
 cells were observed within the CD8
+
 T 
cells from RA patients, suggesting that upregulation of activation markers on this population 
may be more sensitive than on CD4
+
 T cells to denote immune activation. Indeed, the 
frequency of CD69
+
 within the CD8
+
, but not the CD4
+
, T cells showed a significant linear 
correlation with the activity of the disease determined by DAS28 (Figure 1B).  




cells, two clusters of patients with significantly 
different means could be defined within the CD8
+
 population (Figure 1C). One cluster 




 T cells and therefore 
considered to exhibit a “low” T cell activation status. The other cluster comprised patients 




T cells that would denote a status of “high” T cell 
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the CD8
+
 T cells from these “low” and “high” (T cell activation) clusters according to the 
gating strategy depicted in Supplementary Figure 1. Overall, CD8
+
 T cells of patients from 
the “high” cluster showed increased expression of IRs (particularly PD-1 and CD160) in 
comparison to counterparts of patients from the “low” cluster (Supplementary Figure 2). 
Remarkably, the frequency of CD8
+
 T cells co-expressing four IRs or different IR 




 T cells in patients 
from the “high” cluster, indicating that high CD8
+
 T cell activation is linked to IR 
upregulation during RA (Figure 1D and data not shown). In contrast, this correlation was not 
observed within the CD8
+
 T cells from patients from the “low” cluster or HD (Figure 1D), 
yet these cells exhibited variable IR expression that may be rather linked to a cell dysfunction 
stage as consequence of sustained chronic stimulation. 
 
Frequency of IR-expressing T cells is reduced in untreated RA patients and increases 
upon successful treatment  
We next evaluated whether IR expression on T cells from RA patients with active disease but 





 T cells that expressed multiple IRs (PD-1, CD160, Tim-3 and 
BTLA) in HD and RA patients from the “low” cluster. RA patients were divided according to 
treatment in untreated (uTx), DMARDs and anti-TNF+/-DMARDs. As illustrated by the pie 
charts in (Supplementary Figure 3A), CD8
+
 T cells from uTx-RA patients show reduced 
frequencies of cells expressing multiple (two, three and four) IRs in comparison to 
counterparts from HD. Remarkably, the frequencies of IR-expressing CD8
+
 T cells tended to 
increase in DMARDs and anti-TNF+/-DMARDs treated patients. Statistical analysis 
confirmed that the percentage of CD8
+
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(Supplementary Figure 3B) as well as those expressing particular combinations of three IRs 
(Supplementary Figure 3C) were significantly reduced in uTx-RA patients. Given that treated 
patients included patients showing good, moderate and bad response to treatment according 
to EULAR criteria, we performed a longitudinal analysis to determine the dynamic evolution 
of the IR expression patterns according to the clinical response after 3 months of treatment 
(t=3). Responder RA (rRA) patients exhibited an increase in the frequency of CD8
+
 T cells 
that expressed four and three IRs at t=3 in comparison to baseline (t=0). In contrast, no 
significant changes in the frequency of CD8
+
 T cells expressing different IRs combinations 
were observed in non-responder (nrRA) patients (Supplementary Figure 3D and 3E).  
As the frequencies of T cells expressing four or three IRs were low and their study may be 
limiting at clinical level, we assessed whether changes in the expression of two or one IR 
could provide a more robust measure of therapy success. From the four IRs tested, we 
focused on CD160 and PD-1 that were the IRs expressed at higher frequencies. The 
percentage of CD8
+
 T cells expressing PD-1 and CD160, but not those expressing only one 
IR, were significantly decreased in uTX-RA patients in comparison to HD and tended to 
increase in treated RA individuals (Figure 2A). Importantly, the increase in the frequency of 
CD8
+
 T cells expressing one or two of these IRs correlated to treatment response (Figure 2B 













 single positive CD8
+
 T cells 
while reduced double negative CD8
+
 T cells (Figure 2B and 2C). In contrast, nrRA patients 
showed a reduction or no changes in the CD8
+
 T cells expressing one or two IRs and a 
significant increase in the double negative cells (Figure 2B and 2C). We also identified some 
combinations of IRs expressed on CD4
+






) that correlated 
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Reduced IR-expressing CD8
+
 T cells are linked to increased effector function and 
activity of the disease in RA patients with low immune activation.   
Next, we aimed at understanding how the changes in frequencies of IR-expressing CD8
+
 T 
cells observed in RA patients undergoing treatment influenced effector cytokines production 
upon activation. We determined that rRA patients had a frequency of CD8
+
 T cells secreting 
TNF, IFNγ and IL-2 as low as HD. In contrast, nrRA patients that showed no changes in IR 
expression upon treatment exhibited significantly increased percentages of CD8
+
 T cells 
producing effector cytokines in comparison to rRA patients and HD (Figure 3A). Also, CD4
+
 
T cells from nrRA patients contained significantly augmented frequency of cells producing 
effector cytokines such as TNF, IFNγ, IL-2 and IL-17 when compared to counterparts from 
rRA patients and/or HD (Figure 3B).    
Considering that the frequency of IR-expressing T cells in RA patients was inversely 
associated with production of effector cytokines, we speculated that IR expression on T cells 
could also correlate with a more comprehensive clinical parameter such as the activity of the 




 T cells 
expressing different IRs combinations correlated with DAS28 in the total cohort of patients 
involved in this study, including patients untreated (T=0) and treated during 3 (T=3) and 6 
(T=6) months. This analysis showed a negative correlation between DAS28 and the 
frequencies of CD8
+
 T cells expressing PD-1 and CD160 together (Figure 3C, left graph) and 
individually (Figure 3C, middle and right graphs). Furthermore, similar negative correlations 
were observed among DAS28 and CD8
+
 T cells expressing four (Supplementary Figure 3E), 
and particular combinations of three (Supplementary Figure 3F) IRs. This negative 
correlation was also found for some patterns of IR expression on CD4
+
 T cells 
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Altogether our data indicate that in patients exhibiting low T cell activation, reduced 




 T cells upon therapy significantly correlated 
with increased production of effector inflammatory cytokines and more severe activity of the 
disease.  
 
Synovial fluid is enriched in effector CD8
+
 T cells that exhibit a potent cytokine 
producing function that inversely correlated with IR expression  
To establish the biological events undergoing at inflammatory sites during RA, we collected 
SF and evaluated the composition of the immune infiltrate in comparison to the paired PB 
samples. The CD45
+
 cell SF infiltrate was composed of around 20% lymphocytes, while the 





 T cells in SF showed similar frequencies and a strong positive correlation 
with the frequencies in the paired PB samples (Supplementary Figure 4B and C and data not 
shown). Similar to previous reports (20), we observed that central and effector memory 
subsets were significantly increased while naïve and terminal effector subsets were 
significantly reduced within the CD8
+
 and the CD4
+
 T cells from SF in comparison to the 
paired PB (Supplementary Figure 4D and 4F). Interestingly, after 3 months of treatment rRA, 




 T cells 
with terminal effector phenotype (Supplementary Figure 4E and 4G). Next, we performed 
functional studies and determined that synovial CD8
+
 T cells produced higher levels of TNF, 
IFNγ and IL-2 than their peripheral counterparts and that there were significant positive 
correlations between the frequencies of cytokine-producing CD8
+
 T cells from SF and the 
paired PB (Figure 4A). Detailed phenotypic studies showed that the highly activated effector 
CD8
+
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that the percentage of synovial CD8
+
 T cells expressing four IRs showed a positive 
correlation with the paired PB (Figure 4B and Supplementary Figure 2). These results show 
that, somehow expected given its inflammatory nature, SF exhibit overall increased 
frequencies of IR-expressing and cytokine-producing T cells in comparison to the paired PB. 
Importantly, although the frequency of IR-expressing CD8+ T cells was low in PB, there was 
a significant positive correlation with those in the paired SF. We also determined that 
synovial CD8
+




(Figure 4C), previously associated to poor effector function (19).  
We next, evaluated the correlation of IR-expression and effector cytokine production within 
SF and observed that, in complete agreement with the result obtained in PB for rRA versus 
nrRA patients (Fig. 3A), the frequency of IR-expressing synovial CD8
+
 T cells inversely 
correlated with the percentage of synovial cells producing effector cytokines (Figure 4D). 
Therefore, even in the complex environment of an inflammatory site such as synovia, a 
higher expression of IRs within the CD8
+




 T cell population, only IFNγ and IL-17 producing cells were increased in 
SF versus the paired PB but there was no correlation between the frequencies of these cells in 
SF and PB (Supplementary Figure 5A and 5B). Furthermore, although a high percentage of 
synovial CD4
+
 T cells expressed multiple IRs, there was no correlation with the paired PB or 
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Inhibitory pathways are operative to regulate proliferation and cytokine production by 
synovial and peripheral T cells from RA patients.  
We finally investigated whether IRs are functional in T cells from RA patients and could be 
exploited to control ongoing inflammatory response. For this, we developed an assay to 
evaluate how T cell activation was affected by ligation of CD160/BTLA and/or PD-1 using 





 T cells from HD as well as rRA and nrRA patients while PD-
L1:Fc significantly decreased proliferation of CD8
+
 T cells only from rRA patients and CD4
+
 
T cells from rRA and nrRA patients. Remarkably, the combination of HVEM:Fc and PD-
L1:Fc inhibited proliferation of all samples assayed (Figure 5A). Next, we determined that 





 T cells (Figure 5B). Importantly, comparative analysis of the effect observed in 
Figures 5A and B, showed that the combination of HVEM:Fc and PD-L1:Fc could act 





cells from rRA patients and in synovial T cells (Figure 5C). Agonism of CD160/BTLA and 
PD-1 pathways also decreased the frequency of synovial CD8
+
 but not CD4
+
 T cells able to 
produce effector cytokines (Figure 5D). Engagement of IRs expressed on peripheral T cells 
also inhibited effector cytokine production to a variable extent (Supplementary Table 2). Of 
note, stronger IRs ligation induced by higher agonist concentrations leaded to deletion of the 
activated T cells (data not shown).  
Next, we evaluated whether T cell:T cell interactions are able to trigger CD160- and PD-1-





 T cells from HD and RA patients expressed HVEM. Of note, the frequencies of 
HVEM-expressing T cells were significantly reduced in uTx-RA patients in comparison to 
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of CD160/HVEM engagement by an anti-CD160 Ab resulted in higher proliferation of all the 
samples assayed except for CD4
+
 T cells from nrRA patients (Supplementary Figure 6B). 





 T cells from HD and rRA patients, but showed a limited effect in T 
cells from nrRA patients (Supplementary Figures 6C-E).   
In contrast, and despite the fact that a variable frequency of T cells from HD and RA patients 
expressed PD-L1 (unpublished observations), blockade of PD-1/PD-L1 engagement showed 




Different reports showed that polymorphisms in the PD1, CTLA4 and CD244 genes are 
associated with a greater susceptibility to RA and other AIDs (10, 21, 22) while the CD160 
gene is included within gene hubs significantly associated to RA (23). Furthermore, most of 
the patients receiving ‘checkpoint’ blockade as immunotherapy during cancer develop 
immune-related adverse events that involve most organ systems, including the joints (24, 25). 
Maybe more significant from a clinical point of view, recent data indicate that IR-mediated 
pathways, which negatively interfere with T cell activation and function, specifically protects 
against a relapsing course in multiple AIDs.(14) In this context, the regulation of the extent 
and duration of a pathological immune response by IR-mediated pathways may emerge as a 
relevant mechanism dictating the clinical course of the disease once it is established (26). We 
focused in RA and determined that patients showing a “high” T cell activation defined by 
high expression of CD69 on peripheral CD8
+
 T cells exhibited an increased frequency of IR-
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(18). Recently, increased expression of TIGIT on the surface of CD4
+
 T cells was associated 
with a higher DAS28 and increased evidence of inflammation in RA patients (27). Given that 
T cell activation results in the transient upregulation of some IRs (18), it is likely that the 
TIGIT
+
 T cells identified by Luo and colleagues include activated T cells with increased 
potential to proliferate and produce effector cytokines. In contrast, our results indicated that 
the IR-expressing CD8
+
 T cells from RA patients with “low” T cells activation are more 
likely undergoing terminal differentiation (i.e. exhaustion), a T cell differentiation stage 
associated with multiple and sustained IR expression (28). Interestingly, in these patients, the 
frequency of CD8
+
 T cells expressing multiple IRs as well as those showing a phenotype 
compatible with terminal effector cells (TEMRA) increased upon successful treatment and 
inversely correlated with T cell effector function and the clinical activity of the disease. 
These data highlight that expression of activation/differentiation markers and multiple IRs in 
T cells could be useful markers of prognosis and treatment success in RA.  
Recently, induction of T cell exhaustion has been suggested as a novel therapeutic approach 
for AIDs (26). In this line, some reports demonstrated that agonism of the PD-1 pathway 
regulated peripheral and synovial T cell responses during experimental and human RA (11, 
12). However, many RA patients showed resistance to the PD-1 mediated inhibition likely as 
consequence of the presence of a decoy sPD-1 in the inflammatory environment (10, 13). Our 
results agree with these findings and further extend them as we showed that responsiveness to 
PD-1 ligation is conserved only in RA patients that exhibited good response to therapy. 
Furthermore, we determined that PD-1 inhibitory pathway is not triggered by T cell:T cell 
interactions and likely requires the presence of other PD-L1+ immune cells such as 
monocytes. We also addressed the role of additional IRs such as CD160 and BTLA as both 
belong to a bidirectional signaling network that critically modulates T cell biology. Within 
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regulatory cells or T cells) is able to ligate the both BTLA and CD160 on T cells to transduce 
inhibitory signals. These negative signals may be counterbalanced by costimulatory signals 
delivered after direct engagement of HVEM on T cells by LIGHT expressed on DC or other 
T cells (29). During different biological conditions (homeostasis, infection, autoimmunity or 
cancer) it may be a predominance of the negative over the positive signaling or vice versa as 
result of differences in ligand/receptor affinity and/or the differential expression pattern of 
these molecules on cell types at different stages of cell differentiation (30). In this regard, we 
determined that agonism of the IRs CD160 and BTLA suppressed proliferation and/or 




 T cells from 
most RA patients. In addition, we also demonstrated that at least the CD160-mediated 
inhibitory signal can be triggered by T cell:T cell interactions. More importantly, we showed 
that combination of PD-1 and CD160/BTLA ligands exerted a synergistic inhibitory effect on 
T cells from all RA patients, including those that showed poor response to regular treatments.    
Altogether, our and others data highlight that IRs play critical roles in the modulation of the 
ongoing inflammatory response and immunopathology during RA and put forward the notion 
that triggering these inhibitory pathways at local or systemic level may emerge as a rational 
approach for the treatment of refractory RA. 
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Figure legends.  
Figure 1. Evaluation of T cell activation status and IR expression. A, Frequency of 
CD69
+




 T cells from HD and RA patients. 
Median±interquartile range is shown. B, Correlations of frequencies of CD69
+





 T cell gates with DAS28 from RA patients. C, Histogram of distribution of 
the frequencies of CD69
+
 cells within CD8+ T cell gate from RA patients. The cut-off value 
of 10 allowed to define two clusters of RA patients showing “low” and “high” T cell 









 cells and CD69
+
 cells within CD8
+
 T cell gate in RA patients 
from the “high” and “low” clusters and HD. Statistical analysis: p values calculated with 
Mann-Whitney Test (A and C) and with Pearson’s correlation coefficient (B and D). 
Figure 2. Changes in the frequency of PD-1 and/or CD160 expressing T cells were 
linked to clinical response to treatment.  A, Pie charts showing the average values and 
symbol plot showing the individual values of the frequencies of peripheral CD8
+
 T cells 
expressing different color-coded combinations of PD-1 and CD160 in samples from HD, 
untreated (uTx-RA), and DMARDs and anti-TNF±DMARDs treated RA patients. B, 
Representative dot plots showing the frequency of peripheral CD8
+
 T cells expressing PD-1 
and CD160 in one rRA and one nrRA patient in paired samples at baseline (T0) and 3 months 
post-treatment (T3). Changes in DAS28 are indicated above the plots. C, Pie charts showing 
the average values and symbol plots showing the individual values of the frequencies of 
peripheral CD8
+
 T cells expressing different color-coded combinations of PD-1 and CD160 
in paired samples from rRA and nrRA patients at T0 and T3. Statistical analysis: p values 
calculated with One-way Anova followed by Bonferroni post-test (A) and Student’s paired T 
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Figure 3. Frequency of IR-expressing T cells inversely correlated to inflammatory 
cytokine production and activity of the disease. A-B, Frequency of cells producing the 
indicated effector cytokines within peripheral CD8
+
 (A) and CD4
+
 (B) T cell gates in HD, 
rRA and nrRA patients. Mean±DS is shown. C, Correlations between the frequencies of 
peripheral CD8
+
 T cells expressing PD-1 and CD160 together, and PD-1 and CD160 
individually and DAS28 from RA patients. Datasets include RA patients at the indicated 
times post-treatment. Statistical analysis: p values calculated with One-way Anova followed 
by Bonferroni post-test (A and B) and Pearson’s correlation coefficient (C). 
Figure 4. Synovial CD8
+
 T cells exhibited potent effector function that inversely 
correlated with IR expression. A, Comparison and correlations between the frequencies of 
CD8
+
 T cells producing effector cytokines in paired SF and PB samples. B, Comparison and 
correlation between the frequencies of CD8
+
 T cells that express four IRs in paired SF and 







 T cells in paired SF and PB. D, Correlation between the 
frequencies of synovial CD8
+
 T cells that produce effector cytokines and express four IRs. 
Statistical analysis: Student’s paired T test and Pearson’s correlation coefficient (A and B), 
Mann-Whitney Test (C), and Pearson’s correlation coefficient (D). 
Figure 5. Inhibitory pathways mediated by PD1/PD-L1 and HVEM/CD160/BTLA were 




 T cells from PB (A) and SF 
(B) of HD, rRA and nrRA after stimulation in the absence or presence of HVEM:Fc, PD-
L1:Fc and their combination. C, Proliferation index calculated according to data from A and 




 T cells from SF producing the indicated effector 
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Table1. Demographic and clinical characteristics of RA patients and healthy donors  
 Healthy 
Donors (HD) 
 Rheumatoid Arthritis Patients 
(RA) 
Age range (years) 30 - 66   22 - 78 
Blood donors / SF donors 26 / -     51 / 10 
Sex: Female / Male 23 / 3  42 / 9  
Disease activity  
(DAS28-ESR) 















4 ± 2 
 







 Active disease 
(DAS28≥2,6) 
 43 15 ± 9 5 ± 6 4.4±1.0 28/15 26/17 
Treatment        
 uTx  25 19 ± 13 7 ± 13 4.3±1.1 15/10 14/11 
 DMARDs  13 5 ± 5 5 ± 4 3.6±1.5 8/5 5/8 
 TNF inhibitors  13 13 ± 15 5 ± 4 4.1±1.5 11/2 11/2 
 
ESR: erythrocyte sedimentation rate, DAS: disease activity score, CRP: C-reactive protein, 
uTx: untreated, DMARDs: Disease Modifying Anti-Rheumatic Drugs, RF: rheumatoid 
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